Literature DB >> 30954402

DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse.

Doria Filipponi1, Alexander Emelyanov1, Julius Muller2, Clement Molina1, Jennifer Nichols3, Dmitry V Bulavin4.   

Abstract

Accumulating evidence supports the role of the DNA damage response (DDR) in the negative regulation of tumorigenesis. Here, we found that DDR signaling poises a series of epigenetic events, resulting in activation of pro-tumorigenic genes but can go as far as reactivation of the pluripotency gene OCT4. Loss of DNA methylation appears to be a key initiating event in DDR-dependent OCT4 locus reactivation although full reactivation required the presence of a driving oncogene, such as Myc and macroH2A downregulation. Using genetic-lineage-tracing experiments and an in situ labeling approach, we show that DDR-induced epigenetic reactivation of OCT4 regulates the resistance to chemotherapy and contributes to tumor relapse both in mouse and primary human cancers. In turn, deletion of OCT4 reverses chemoresistance and delays the relapse. Here, we uncovered an unexpected tumor-promoting role of DDR in cancer cell reprogramming, providing novel therapeutic entry points for cancer intervention strategies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA damage signaling; DNA methylation; Myc; OCT4; SIRT1; WIP1 phosphatase; cancer relapse; macroH2A; reprogramming

Mesh:

Substances:

Year:  2019        PMID: 30954402     DOI: 10.1016/j.molcel.2019.03.002

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  4 in total

1.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

2.  Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma.

Authors:  Doria Filipponi; Marina Pagnuzzi-Boncompagni; Gilles Pagès
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

3.  Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.

Authors:  Arup R Chakraborty; Alex Vassilev; Sushil K Jaiswal; Constandina E O'Connell; John F Ahrens; Barbara S Mallon; Martin F Pera; Melvin L DePamphilis
Journal:  Stem Cell Reports       Date:  2022-01-20       Impact factor: 7.294

4.  Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer.

Authors:  Haiyun Zhang; Alexander Steed; Milo Co; Xiaozhuo Chen
Journal:  Cancer Drug Resist       Date:  2021-06-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.